Here It Goes, Here It Goes, Here It Goes Again: The Build Back Better Act (Redux)
FDA Law Blog
JULY 13, 2022
With 190 pages dedicated to prescription drug pricing reform, the program is ambitious…and complicated. As a threshold matter, the 2-year delay provision does not solve the core problem for biosimilars manufacturers: the lack of predictability that Build Back Better injects into biosimilar development.
Let's personalize your content